Advanced lung cancer

Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


The FDA ( Food and Drug Administration ) has granted full approval for Tagrisso ( Osimertinib ) 80mg once-daily tablets,...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small...


Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage...


In non-small cell lung cancer ( NSCLC ) that has already formed metastases, the suitable treatment depends, among other factors,...



The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, for the...


The FDA ( Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) for the treatment of people with...


The aim of a study was to explore the efficacy and safety of Crizotinib ( Xalkori ) versus Platinum-based double...


The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a...


Epacadostat is an oral, potent, selective inhibitor of indoleamine 2,3-dioxygenase 1 ( IDO1 ), a tryptophan-catabolizing enzyme that induces immune...


The FDA ( Food and Drug Administration ) has granted Priority Review for Atezolizumab ( anti-PD-L1; MPDL3280A ) for the...


The FDA ( Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) to treat the most common type...


Two-year overall survival data from two pivotal phase 3 studies evaluating Nivolumab ( Opdivo ) versus Docetaxel in previously treated...


The baseline serum cytokine levels of Platinum pretreated patients with advanced squamous non-small cell lung cancer ( NSCLC ) altered...


Patients with epidermal growth factor receptor ( EGFR ) expressing advanced squamous non-small-cell lung cancer benefit most from Necitumumab (...


The European Commission ( EC ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 therapy, at a dose of 2...


Alectinib ( Alecensa ), an oral anaplastic lymphoma kinase ( ALK ) inhibitor, has reduced the risk of disease worsening...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat...


Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. Researchers have assessed the activity...